Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Non-Deal Roadshow (April 2017)
21 slides from Elekta Ab Class B's roadshow presentation, Apr 25, 2017
Slide 1: Elekta London road show
Elekta London road show Richard Hausmann, President and CEO April 25, 2017
Slide 2: Elekta – global leader in radiation therapy
Elekta – global leader in radiation therapy • One of the two major global companies in radiation therapy • Active on 120 markets globally • ~40% global market share; leader in Asia Pacific and Europe • Over 1 M treatments per year • 3,700 installed systems • 3,600 employees worldwide • Net sales SEK
Slide 3: Radiation therapy – underlying growth potential
Radiation therapy – underlying growth potential Lack of capacity • At least 10,000 additional linacs are required to meet current needs* Underlying growing need Innovation enable • New cancer cases to grow from 15 M per year to 24 M by 2035 broader usage • Additional cancer types • Increased recurre
Slide 4: Oncology Informatics Portfolio and treatment solutions
EMR PARTICAL RADIATION ONCOLOGY & MEDICAL THERAPY ONCOLOGY INFORMATICS Treatment pathway centric REGISTRY Vendor & therapy agnostic Localized to markets SERVICES & SUPPORT MOSAIQ MOSAIQ MOSAIQ METRIC/LGK Oncology specific EMR Oncology Analytics Image & Plan Review Cancer Registries SURGERY Oncology
Slide 5: Elekta's revenue base (Q3 rolling 12 months)
Elekta’s revenue base (Q3 rolling 12 months) Oncology Informatics Oncology informatics Linear 16% Accelerators* Linear 16% Brachy- accelerators* Brachy therepy* 62% 9% 9% Therapy* 62% 13% Neuroscience* 13% Neuroscience* 5 | Focus where it matters *Including treatment planning software and service
Slide 6: Market position in linear accelerators
Market position in linear accelerators NEW ORDERS* NEW SOCKETS** INSTALLED BASE Other Other 10% Other 12% 23% Elekta Elekta 41% Elekta 24% 47% Varian Varian Varian 49% 41% 53% *Order intake of linear accelerators last twelve months **New radiation therapy departments or expansion by new bunker 6 | F
Slide 7: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 7
Slide 8: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation “To create the possible we have to constantly try the impossible” Hermann Hesse 8
Slide 9: The innovation opportunities for radiotherapy
The innovation opportunities for radiotherapy More outcome and focus where it matters Image guidance Workflow Automation • High field MR as the • Integrated and automated • Big data applications ultimate soft tissue workflows on treatment imaging tool units • Decision support with self learning • Ad
Slide 10: Wrapping high dose tightly to a target is sufficient in static situations
Wrapping high dose as tight as possible to a target is sufficient in static situations… 10 | Focus where it matters
Slide 11: Targets often move and only advanced imaging helps reduce margins
…but targets often move and only advanced imaging helps reduce margins and further limit dose to healthy tissue… 11 | Focus where it matters
Slide 12: Day-to-day changes require seamless on-line plan adaptation
…and for day-to-day changes of shape and position, seamless and on-line plan adaptation is vital. ONLINE ADAPTIVE • Diagnostic Imaging • Dose Calculation • Dose Adjustment • Repositioning • Plan Adaptation
Slide 13: MR-Linac
MR-Linac Cone Beam IGRT (New) (Today) Esophagus MR-Linac Bladder Brings together the capability of high-field diagnostic MR imaging, the highest standard of precision radiation therapy delivery and sophisticated adaptive workflow software for the first time. Rectal tumor
Slide 14: How to navigate in today's RT-world
How to navigate in todays RT-world Plan dose Adaptive navigation provides actual information to decide how to best reach destination Anatomical changes IGRT added navigation Patient moves Faster cars Arrive at actual delivered dose 14 | Focus where it matters 14
Slide 15: 12 MR-linac customers to date
7 consortium sites 5 commercial systems 12 MR-linac customers to date Ambition: Launch in 75 orders H2 calendar until 2019 year 2017 Note: all in line with local regulatory requirements
Slide 16: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 16
Slide 17: Transformation for profitable growth on track
Kan vi göra denna Transformation for snyggare? profitable growth on track Objectives • Improve processes and structure • Reduce cost and restore profitability • Strengthen cash flow and reduce working capital • Improve customer experience and drive excellence in product development
Slide 18: Ambition is to improve EBITA margin to >20%
Ambition is to improve EBITA margin to >20% Margin development* (illustrative) Transformation program targets EBITA margin of >20% by 2017/18 47% 46% 43% 41% 41% 40% Cost reductions of Net working capital Produce-to-order 23% 22% SEK 700**M to sales below process. One-off 20% 14% 15% 16% with full e
Slide 19: Net working capital at 1% of net sales
Net working capital at 1% of net sales* KEY WORKING CAPITAL ASSETS 4 000 NET WORKING CAPITAL as % of SALES Accounts 15% 3 000 receivables 2 000 Accrued 10% income 1 000 5% Inventories 0 1,0% Q3 15/16 Q4 15/16 Q1 16/17 Q2 16/17 Q3 16/17 0% 1601AC 1604AC 1607AC 1610AC 1701AC KEY WORKING CAPITAL LIABIL
Slide 20: Unique position, strong product offering, transformation on track
UNIQUE POSITION in long-term growing market STRONG PRODUCT OFFERING and leading R&D portfolio TRANSFORMATION ON TRACK for operational excellence and profitable growth
Slide 21: Focus where it matters.
Focus where it matters. t. Ad CyElekta